The webinar will provide an overview of the scientific rationale for this exciting planned trial as well as discuss the next steps forward.
ALS TDI To Hold TDI132 Information Webinar on March 12th
Webinar: TDI 132 Information
March 12, 2012
This February, the ALS Therapy Development Institute announced that it plans to launch a clinical trial on a potential treatment for ALS called TDI 132 (aka fingolimod or Gilenya®). The March webinar will focus on this effort. The webinar will provide an overview of the scientific rationale for this exciting planned trial as well as discuss the next steps forward. Drs. Steve Perrin (ALS TDI) and James Berry (MGH/HMS) will be panelists for this discussion.
Watch the archived webinar here.
U.S. News & World Report ranks Mass General #2 in the nation and #1 in New England based on our quality of care, patient safety and reputation in 16 clinical specialties.
Search the archive for previously published news articles, press releases and publications.
Departments and Centers at Mass General have a reputation for excellence in patient care. View a list of all departments.